


**Figure 1**

Figure 2




Figure 3

Clinicopathologic features and outcome of 12 consecutive patients with relapsed acute promyelocytic leukemia treated with oral  $As_2O_3$

sex / age status	previous induction treatment	Time from			Oral $As_2O_3$ therapy		Consolidation	Latest PCR <sup>1</sup>	DFS	Remarks
		last CR	Hb	relapse WBC	Plat	duration	additional Rx			
1* M / 23	R1 R2	11 m	15.6	2.1	87	59 d	Ida	CR	13 m	
2* M / 33	R2	10 m	14.0	2.5	25	76 d	ATRA	NR	+	(dead)
3* F / 13	R2	25 m	13.4	2.1	20	32 d	ATRA	CR	As <sub>2</sub> O <sub>3</sub> + ATRA	19 m +
4 M / 54	R1	12 m	8.6	1.2	15	30 d	ATRA	CR	As <sub>2</sub> O <sub>3</sub> + ATRA	19 m +
5* M / 32	R1	100 m	8.5	34.8	81	40 d	Ida	CR	Ida	18 m +
6 F / 32	R1	22 m	14.5	2.4	177	33 d	-	CR	Ida	18 m +
7* F / 45	R2	12 m	12.2	0.8	84	51 d	-	CR	Ida	18 m +
8 F / 65	R1	17 m	11.2	1.9	50	37 d	ATRA	CR	As <sub>2</sub> O <sub>3</sub> + ATRA	17 m +
		16 m	7.2	2.8	141	28 d	-	CR	As <sub>2</sub> O <sub>3</sub> + ATRA	15 m +
9 F / 18	R2	12 m	10.1	1.9	180	28 d	ATRA	CR	As <sub>2</sub> O <sub>3</sub> + ATRA	14 m +
10* F / 18	R1	12 m	8.2	12.6	54	44 d	Ida	CR	Ida	9 m +
11* M / 45	R1	240 m	4.2	0.6	9	22 d	-	CR	As <sub>2</sub> O <sub>3</sub>	7 m +
12 F / 40	R1	23 m	8.5	6.5	39	28 d	Ida	CR	Ida	6 m +

\*: pharmacokinetic data of oral  $As_2O_3$  have previously been reported<sup>6</sup>

1: PCR for *PML/RARA*, +: positive, -: negative, (time from initial diagnosis)

M: male; F: female, CR: complete remission; NR: non-remission; R1: first relapse; R2: second relapse

CBC: complete blood count; Hb: hemoglobin (g/dL); WBC: white blood cell count ( $\times 10^9/L$ ); Plat: platelet count ( $\times 10^9/L$ )

m: months; d: days; DFS: disease free survival

ATRA: all-trans retinoic acid; Dauno: daunorubicin; Ida: idarubicin; Ara-c: cytosine arabinoside

CA: carcinoma; AML: acute myeloid leukemia; CRF: chronic renal failure; DM: diabetes mellitus

CAPD: continuous ambulatory peritoneal dialysis; CRHD: chronic rheumatic heart disease; rep: replacement

CRF due to DM on CAPD,  
Ida consolidation omitted due  
to CRF

Ida consolidation omitted due  
to high cumulative doses of  
anthracycline

CRHD, double valve rep